Finch Therapeutics initiates Nasdaq delisting; plans SEC deregistration by Nov 11

Finch Therapeutics Group, Inc.

Board determined to delist common stock from Nasdaq; Form 25 to be filed on or about Oct 31, 2024.
Delisting effective 10 days after Form 25 filing; trading to continue on OTC Markets Group.
Form 15 to be filed on or about Nov 11, 2024 to deregister under Exchange Act; reporting obligations suspended immediately.
Board cites cost savings from SEC reporting, Sarbanes-Oxley compliance, and prior non-compliance (public shell, market value deficiency).
Common stock suspended from Nasdaq since May 28, 2024 due to Nasdaq's public shell determination.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.